Dupilumab generic?

When Will Dupilumab Go Off-Patent?

Dupilumab, a biologic treatment for atopic dermatitis and asthma, is marketed under the brand name Dupixent by Sanofi and Regeneron. [1]

Is Dupilumab Patent Protection Fading?

Dupilumab is currently protected by patents with various expiry dates. According to DrugPatentWatch.com, the patent for Dupixent in the United States expires in 2034 [2]. However, it's crucial to note that regulatory exclusivity typically ends a few years before patent expiration. In this case, the exclusive marketing rights for Dupixent in the US are set to expire in 2032. [3]

What's Happening as the Patent Fades?

While patent protection is not yet at an end, generic versions or biosimilar alternatives may become increasingly competitive. Companies such as Amgen and Fresenius Kabi are actively working on developing their versions of Dupilumab [4]. Sanofi and Regeneron face pressure as competition grows, but regulatory hurdles and ongoing clinical development can influence this process.

How Will the Patent Expiration Impact Pricing and Access?

As patented protection fades and regulatory exclusivity ends, generic and biosimilar options may reduce pricing pressure, potentially increasing access to more patients. The market dynamics are complex, and prices for Dupixent may not automatically decrease. However, regulatory policies, healthcare budgets, and insurance coverage could ultimately influence pricing and patient access.

Sources:

[1] Sanofi and Regeneron Pharmaceuticals, Dupixent (dupilumab) [online]. Available at: https://www.dupixent.com

[2] DrugPatentWatch, Dupilumab (Dupixent) Patents & Exclusivities [online]. Available at: https://www.drugpatentwatch.com/drugs/Dupilumab

[3] U.S. Food and Drug Administration, Dupixent (dupilumab) [online]. Available at: https://www.fda.gov/drugs/atf-a-drug-products/dupixent-dupilumab